The Increased Product Launch is Propelling the Growth of the Glioblastoma Multiforme Treatment (GBM) Market in the APAC Region!

The Asia-Pacific (APAC) region is an important and growing market for glioblastoma multiforme (GBM) treatment market. The region includes countries such as China, India, Japan, and Australia, which have large and rapidly aging populations, and increasing incidence of brain tumors, including GBM. The APAC GBM treatment market is driven by factors such as the increasing prevalence of brain tumors, the growing demand for personalized cancer treatment options, and the rising adoption of advanced diagnostic and treatment technologies. For instance, in July 2020, Cadila Pharmaceuticals launched cancer named Bavaro in India. The drug is used to treat multiple cancers including glioblastoma multiforme.

Request For Sample PDF-https://univdatos.com/report/glioblastoma-multiforme-treatment-gbm-market/get-a-free-sample-form.php?product_id=38265

Further, the Asia-Pacific Glioblastoma Multiforme Treatment (GBM) market was valued at USD 2 billion in 2021 & is expected to grow at a CAGR of 8% from 2022-2030. For instance, in December 2022, The Australian Brain Tumor Mission invested USD 136.66 million to support brain tumor research. The goal is to double survival rates and improve the quality of life for brain tumor patients.

APAC Glioblastoma Multiforme Treatment (GBM) Market Revenue (2020-2030)- USD Mn

Based on treatment, the market is segmented into surgery, radiation therapy, chemotherapy, targeted therapy, tumor treating Field (TTF) therapy, and immunotherapy. The radiation therapy segment acquired a major share in 2021. Radiation therapy uses high-energy radiation to kill cancer cells and shrink tumors. It is often used in combination with other treatments, such as surgery and chemotherapy, to improve the chances of success. The increasing incidence of brain tumors, the growing demand for personalized cancer treatment options, and the rising adoption of advanced radiation therapy technologies are the major attributing factor to the considerable share of radiation therapy in the GBM treatment market.

Based on the end-use, the market is segmented into hospitals, clinics, ambulatory surgical centers, and others. The clinics segment is expected to grow with the highest CAGR during the forecast period. The clinics in the GBM treatment market offer a variety of services, including imaging and diagnostic tests to confirm the presence of GBM, surgical procedures to remove tumors, radiation therapy to kill cancer cells, and chemotherapy to destroy cancer cells that have spread to other parts of the body are the main reason for the segmental growth.

Global Glioblastoma Multiforme Treatment (GBM) Market Segmentation

Market Insight, by Treatment

· Surgery

· Radiation therapy

· Chemotherapy

· Targeted Therapy

· Tumor Treating Field (TTF) Therapy

· Immunotherapy

Market Insight, by End-Use

· Hospitals

· Clinics

· Ambulatory Surgical Centers

· Others

Market Insight, by Region

· North America

o U.S.

o Canada

o Rest of North America

· Europe

o Germany

o UK

o France

o Italy

o Spain

o Rest of Europe

· APAC

o China

o Japan

o India

o Rest of APAC

· Rest of the World

Top Company Profiles

· Merck & Co., Inc.

· Amgen Inc.

· F. Hoffmann-La Roche Ltd

· Pfizer Inc.

· Teva Pharmaceutical Industries Ltd.

· Sun Pharmaceutical Industries Ltd.

· Amneal Pharmaceuticals LLC

· Karyopharm

· Sumitomo Pharma Oncology, Inc

· Bristol-Myers Squibb Company